B+
Bull case
25%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
CATX
Perspective TherapeuticsANYSE American / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The ESMO update reported 33% and 50% objective response rates in Cohorts 2 and 3, respectively, including unconfirmed responses, and a 72% 18-month progression-free-survival rate across cohorts. Favorable follow-up and FDA alignment could strengthen the development case [#8-K-2026-10-23].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.6.
What can break
Interim, nonrandomized VMT-α-NET data may not translate into Phase 3 efficacy; Cohort 3 includes unconfirmed responses [#8-K-2026-10-23].
Momentum
27
Value
57
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.45 · Bull $2.50 · Bear $0.70Analysis 2026-10-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $12.23
Why
Momentum27 · Δ7d -2.5
Value57 · Δ7d +16.7
Sentiment100 · Δ7d +2.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +2.6.
Contradictions & invalidation
- • Interim, nonrandomized VMT-α-NET data may not translate into Phase 3 efficacy; Cohort 3 includes unconfirmed responses [#8-K-2026-10-23].
- • Phase 3 timing depends on FDA alignment, protocol finalization and site readiness [#8-K-2026-10-23].
- • The data remain interim and nonrandomized; cohort sizes and follow-up differ, and some responses are unconfirmed.
Catalyst clock
2026-11-05
Additional clinical presentations
Lead driver: Sentiment · See AI snapshot
Momentum
27
8% active weight
Current posture
7d trendImproving
Δ7d
-2.5
Δ21d
+24.1
Value
57
47% active weight
Current posture
7d trendImproving
Δ7d
+16.7
Δ21d
+16.4
Sentiment
100
45% active weight
Current posture
7d trendImproving
Δ7d
+2.6
Δ21d
+3.0
Why this grade
Composite grade A. Momentum 26.6 / Value 57.4 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.45
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.70
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$183.78M
Beta
1.75
Shares Out
114.15M
P/E (TTM) · Derived
-1.2
P/S (TTM)
188.78
P/FCF (TTM) · Derived
-1.23
Rev YoY
-72.1%
EPS YoY
-23.3%
Gross Margin
-891.0%
Op Margin
-28174.1%
Net Debt
-$141.48M
Current Ratio
6.61
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data